Impella RP Post-Approval Study Data Presented at ACC 2019 Data demonstrates survival benefit with the Impella RP Recover Right protocol The Impella RP FDA post-market study data shows 64% survival ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results